Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruby F Meredith

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
Medical Physics|August 14, 2008
Targeted radionuclide therapyLawrence E Williams, Gerald L DeNardo, Ruby F Meredith
Cancer Biotherapy & Radiopharmaceuticals|March 2, 2011
Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinomaSui Shen, Andres Forero, Ruby F Meredith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancerRuby F Meredith, Donald J Buchsbaum, Ronald D Alvarez, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapySui Shen, Ruby F Meredith, Jun Duan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2002
Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapySui Shen, Ruby F Meredith, Jun Duan, et al.
International Journal of Radiation Oncology, Biology, Physics|May 27, 2009
Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neckJimmy J Caudell, Philip E Schaner, Renee A Desmond, et al.
International Journal of Radiation Oncology, Biology, Physics|April 24, 2009
Margin on gross tumor volume and risk of local recurrence in head-and-neck cancerJimmy J Caudell, Ruby F Meredith, Sharon A Spencer, et al.
Advances in Radiation Oncology|May 1, 2023
Biological Effective Radiation Dose for Multiple Myeloma PalliationRuby F Meredith, John R Bassler, Andrew M McDonald, et al.
American Journal of Clinical Oncology|September 1, 2007
Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03William F Hartsell, Charles B Scott, George S Dundas, et al.
Cancer|March 6, 2002
Model prediction of treatment planning for dose-fractionated radioimmunotherapySui Shen, Jun Duan, Ruby F Meredith, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
Medical Physics|August 14, 2008
Targeted radionuclide therapyLawrence E Williams, Gerald L DeNardo, Ruby F Meredith
Cancer Biotherapy & Radiopharmaceuticals|March 2, 2011
Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinomaSui Shen, Andres Forero, Ruby F Meredith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancerRuby F Meredith, Donald J Buchsbaum, Ronald D Alvarez, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapySui Shen, Ruby F Meredith, Jun Duan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2002
Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapySui Shen, Ruby F Meredith, Jun Duan, et al.
International Journal of Radiation Oncology, Biology, Physics|May 27, 2009
Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neckJimmy J Caudell, Philip E Schaner, Renee A Desmond, et al.
International Journal of Radiation Oncology, Biology, Physics|April 24, 2009
Margin on gross tumor volume and risk of local recurrence in head-and-neck cancerJimmy J Caudell, Ruby F Meredith, Sharon A Spencer, et al.
Advances in Radiation Oncology|May 1, 2023
Biological Effective Radiation Dose for Multiple Myeloma PalliationRuby F Meredith, John R Bassler, Andrew M McDonald, et al.
American Journal of Clinical Oncology|September 1, 2007
Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03William F Hartsell, Charles B Scott, George S Dundas, et al.
Cancer|March 6, 2002
Model prediction of treatment planning for dose-fractionated radioimmunotherapySui Shen, Jun Duan, Ruby F Meredith, et al.
Pageof 6